Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period

View ORCID ProfileErik Eik Anda, View ORCID ProfileTonje Braaten, View ORCID ProfileKristin B. Borch, Therese H. Nøst, View ORCID ProfileSairah L. F. Chen, View ORCID ProfileMarko Lukic, View ORCID ProfileEiliv Lund, Frode Forland, David Leon, View ORCID ProfileBrita Askeland Winje, Anne-Marte Bakken Kran, Mette Kalager, View ORCID ProfileFridtjof Lund Johansen, View ORCID ProfileTorkjel M. Sandanger
doi: https://doi.org/10.1101/2021.03.23.21253730
Erik Eik Anda
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erik Eik Anda
  • For correspondence: erik.anda@uit.no
Tonje Braaten
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tonje Braaten
Kristin B. Borch
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kristin B. Borch
Therese H. Nøst
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sairah L. F. Chen
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sairah L. F. Chen
Marko Lukic
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marko Lukic
Eiliv Lund
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eiliv Lund
Frode Forland
2Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Leon
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
3Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brita Askeland Winje
2Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brita Askeland Winje
Anne-Marte Bakken Kran
2Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mette Kalager
4Clinical Effectiveness Research Group, University of Oslo and Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fridtjof Lund Johansen
5Department of Immunology, Oslo University Hospital, Rikshospitalet, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fridtjof Lund Johansen
Torkjel M. Sandanger
1Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Torkjel M. Sandanger
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Since early 2020, over 123 million people worldwide have been diagnosed with coronavirus disease (Covid-19), but the true number of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undoubtedly higher. The seroprevalence of antibodies against SARS-CoV-2 can provide crucial epidemiological information about the extent of infections independent of virologically detected case numbers. There is no large population-based SARS-CoV-2 seroprevalence survey from Norway; thus we estimated SARS-CoV-2 seroprevalence in Norway before the introduction of vaccines and described its distribution across demographic groups. In November-December 2020, a total of 110,000 people aged 16 years or older were randomly selected from the National Population Register and invited to complete a questionnaire and provide a dried blood spot (DBS) sample. The response rate was 30%; compliance rate for return of DBS samples was 88%. The national weighted and adjusted seroprevalence was 0.9% (confidence interval 0.7-1.0).

Seroprevalence was highest among those aged 16-19 years (1.9%, 0.9-2.9), those born outside the Nordic countries 1.4% (1.0-1.9), and in the counties of Oslo 1.7 % (1.2-2.2) and Vestland 1.4% (0.9-1.8). The ratio of SARS-CoV-2 seroprevalence (0.9) to the cumulative incidence of virologically detected cases by mid-December 2020 (0.8%) was slightly above one. SARS-CoV-2 seroprevalence was low before the introduction of vaccines in Norway and was comparable to virologically detected cases, indicating that most cases in the first 10 months of the pandemic were detected. Preventive measures including contact tracing have been effective, people are complying with social distancing recommendations, and local efforts to contain outbreaks have been essential.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The project was funded from the Norwegian Research Council (project number 312730) and UiT The Arctic University of Norway.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study has been approved by the Regional Committee for Medical Research Ethics, North Norway (reference number: 154985/2020) and the Norwegian Data Protection Authority (reference number: 758042/2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* First authors

  • ↵# Last author

  • erik.anda{at}uit.no, tonje.braaten{at}uit.no, kristin.benjaminsen.borch{at}uit.no, therese.h.nost{at}uit.no, sairah.chen{at}uit.no, marko.lukic{at}uit.no, eiliv.lund{at}uit.no, frode.forland{at}fhi.no, david.leon{at}lshtm.ac.uk, brita.askeland.winje{at}fhi.no, anne-martebakken.kran{at}fhi.no, mette.kalager{at}medisin.uio.no, fridtjol{at}gmail.com, torkjel.sandanger{at}uit.no

Data Availability

The datasets analysed during the current study are not publicly available due to local and national ethical and security policies, but can be obtained upon request from the corresponding author in an anonymized format after the study has been published.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period
Erik Eik Anda, Tonje Braaten, Kristin B. Borch, Therese H. Nøst, Sairah L. F. Chen, Marko Lukic, Eiliv Lund, Frode Forland, David Leon, Brita Askeland Winje, Anne-Marte Bakken Kran, Mette Kalager, Fridtjof Lund Johansen, Torkjel M. Sandanger
medRxiv 2021.03.23.21253730; doi: https://doi.org/10.1101/2021.03.23.21253730
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Seroprevalence of antibodies against SARS-CoV-2 virus in the adult Norwegian population, winter 2020/2021: pre-vaccination period
Erik Eik Anda, Tonje Braaten, Kristin B. Borch, Therese H. Nøst, Sairah L. F. Chen, Marko Lukic, Eiliv Lund, Frode Forland, David Leon, Brita Askeland Winje, Anne-Marte Bakken Kran, Mette Kalager, Fridtjof Lund Johansen, Torkjel M. Sandanger
medRxiv 2021.03.23.21253730; doi: https://doi.org/10.1101/2021.03.23.21253730

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (553)
  • Anesthesia (135)
  • Cardiovascular Medicine (1761)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (660)
  • Epidemiology (10803)
  • Forensic Medicine (8)
  • Gastroenterology (592)
  • Genetic and Genomic Medicine (2952)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1930)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (631)
  • Infectious Diseases (except HIV/AIDS) (12519)
  • Intensive Care and Critical Care Medicine (693)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2801)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1469)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (867)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2641)
  • Public and Global Health (5374)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (596)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)